LAB Standard BioTools Inc

Price (delayed)

$0.7809

Market cap

$304.84M

P/E Ratio

3.9

Dividend/share

N/A

EPS

$0.2

Enterprise value

$68.56M

?
Relative Growth: Rel. Growth: 49
Relative Strength: Rel. Strength: 9
Relative Valuation: Rel. Valuation: 97
Relative Profitability: Rel. Profitability: 68

Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions ...

Highlights
Standard BioTools's EPS has soared by 200% from the previous quarter and by 159% YoY
The company's net income has surged by 159% YoY
Standard BioTools's gross profit has decreased by 4.7% YoY
Standard BioTools's revenue has decreased by 3.7% YoY

Key stats

What are the main financial stats of LAB

LAB stock price

How has the Standard BioTools stock price performed over time
Intraday
4.48%
1 week
-1.41%
1 month
-32.1%
1 year
-34.93%
YTD
-38.99%
QTD
-15.05%

Financial performance

How have Standard BioTools's revenue and profit performed over time
Revenue
$86.26M
Gross profit
$42.8M
Operating income
-$95.78M
Net income
$78.21M
Gross margin
49.6%
Net margin
90.7%
The net margin has surged by 161% year-on-year
The company's net income has surged by 159% YoY
LAB's operating margin is up by 14% since the previous quarter and by 10% year-on-year
LAB's operating income is up by 13% from the previous quarter and by 13% YoY

Price vs fundamentals

How does LAB's price correlate with its fundamentals

Growth

What is Standard BioTools's growth rate over time

Valuation

What is Standard BioTools stock price valuation
P/E
3.9
P/B
0.54
P/S
3.51
EV/EBIT
1.69
EV/EBITDA
1.25
EV/Sales
0.79
Standard BioTools's EPS has soared by 200% from the previous quarter and by 159% YoY
The price to book (P/B) is 48% lower than the last 4 quarters average of 1.0
Standard BioTools's equity has increased by 32% QoQ and by 23% YoY
The P/S is 35% below the last 4 quarters average of 5.2 and 4% below the 5-year quarterly average of 3.5
Standard BioTools's revenue has decreased by 3.7% YoY

Efficiency

How efficient is Standard BioTools business performance
The ROE has soared by 198% QoQ and by 163% YoY
The company's return on assets has surged by 166% YoY
Standard BioTools's ROS has soared by 136% from the previous quarter and by 132% YoY
The return on invested capital has surged by 134% since the previous quarter and by 128% year-on-year

Dividends

What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LAB.

Financial health

How did Standard BioTools financials performed over time
The current ratio has soared by 195% from the previous quarter and by 102% YoY
LAB's quick ratio has soared by 125% YoY
The debt is 95% smaller than the equity
Standard BioTools's equity has increased by 32% QoQ and by 23% YoY
LAB's debt to equity is down by 29% since the previous quarter and by 29% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.